Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blind Procedures02:07

Blind Procedures

10.8K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.8K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

933
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
933
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
Drug Therapy01:28

Drug Therapy

450
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
450

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroconvulsive Therapy for Adolescents: Review of Ongoing Concerns and Barriers.

AJOB neuroscience·2026
Same author

Back to the future: trace lead in ambient air from wood fuel combustion.

Journal of exposure science & environmental epidemiology·2026
Same author

Neurotechnology Governance in the United States: Gaps and Opportunities.

Bioethics·2025
Same author

Rewriting the Script: The Need for Effective Education to Address Racial Disparities in Transcranial Magnetic Stimulation Uptake in BIPOC Communities.

Neuroethics·2025
Same author

Is the Treatment Worse than the Disease?: Key Stakeholders' Views about the Use of Psychiatric Electroceutical Interventions for Treatment-Resistant Depression.

Neuroethics·2025
Same author

From Scholarship to Practice: Standardizing Calls to Action in Neuroethics.

AJOB neuroscience·2025
Same journal

Burden of Stroke in China From 1990 to 2023: Analysis From the Global Burden of Disease Study 2023.

Online journal of public health informatics·2026
Same journal

Tweets Surrounding Pharmaceutical Drug Brands With Top Direct-to-Consumer TV-Advertising Budgets: Social Media Listening Study.

Online journal of public health informatics·2026
Same journal

The Use of Tomographs in Brazil's National Health System: Case Study on the Efficiency of the Public Network in Rio Grande do Norte.

Online journal of public health informatics·2026
Same journal

Transforming Pediatric Care Through AI: Bridging the Digital Divide in Health Informatics.

Online journal of public health informatics·2026
Same journal

Building Enhanced Public Health Data Systems With a Situational Awareness and Learning Tool: Focus Group Study.

Online journal of public health informatics·2026
Same journal

Assessment of the Cultural Nuances in COVID-19 Vaccine Uptake Through a Comparative Analysis of English and Spanish Facebook Posts in Tarrant County, Texas: Longitudinal Study.

Online journal of public health informatics·2026
See all related articles

Related Experiment Video

Updated: May 7, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.4K

Public Perceptions of Treating Opioid Use Disorder With Deep Brain Stimulation: Comment Analysis Study.

Patricia Henegan1, Jack Koczara2, Robyn Bluhm3,4

  • 1Department of Engineering Science and Mechanics, Pennsylvania State University, University Park, PA, United States.

Online Journal of Public Health Informatics
|August 16, 2024
PubMed
Summary
This summary is machine-generated.

Public views on deep brain stimulation (DBS) for opioid use disorder (OUD) reveal concerns about treatment outcomes, addiction as a disorder, and resource allocation. Understanding these perceptions is key to addressing misinformation about this novel OUD therapy.

Keywords:
DBSaddictioncomment analysisdeep brain stimulationmental healthopioidopioid addictionopioid usepsychiatric disorderrefractory opioid use disordersubstance abusesubstance usetherapeutictreatment

More Related Videos

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.2K
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

8.8K

Related Experiment Videos

Last Updated: May 7, 2026

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
11:12

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Published on: July 16, 2014

22.4K
A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.2K
Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models
14:14

Targeting Neuronal Fiber Tracts for Deep Brain Stimulation Therapy Using Interactive, Patient-Specific Models

Published on: August 12, 2018

8.8K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Bioethics

Background:

  • Opioid-related deaths have surged, necessitating novel treatments for opioid use disorder (OUD).
  • Deep brain stimulation (DBS) is an emerging intervention for psychiatric conditions, including OUD, but faces ethical debate.
  • Limited research exists on the neuroethical implications of using DBS for OUD.

Purpose of the Study:

  • To analyze public perceptions of deep brain stimulation (DBS) for opioid use disorder (OUD).
  • To gain empirical neuroethical insights by examining online comments on news articles about DBS for OUD.

Main Methods:

  • Qualitative thematic content analysis of 292 web-based comments from two Washington Post articles.
  • Focus on identifying predominant themes and shifts in public discourse regarding DBS for OUD.

Main Results:

  • Key themes included expectations for treatment outcomes, the classification of addiction as a mental health disorder, and resource allocation concerns.
  • A decrease in controversial comments and an increase in comments about therapeutic need were observed between the two articles.

Conclusions:

  • Public perspectives on DBS for OUD encompass sociopolitical, technological, and scientific considerations.
  • Understanding these public views can combat misinformation and clarify ethical concerns specific to DBS in OUD treatment.
  • Comparing ethical concerns for DBS in OUD versus other psychiatric disorders is crucial.